AI Drives Major Advances in Healthcare: From Childhood Cancer to Pharmacy Practice
President Trump signs AI-driven pediatric cancer research order as pharmacists adopt AI to enhance care and operations.
- • President Trump signed an executive order to boost AI use in childhood cancer research.
- • The AI market is projected to grow from $25 trillion to $29 trillion in 2025.
- • Pharmacists use AI and telepharmacy to expand patient care and improve pharmacy functions.
- • Ethical challenges like data privacy and algorithmic bias require human oversight in AI deployments.
Key details
President Donald Trump recently signed an executive order to intensify the use of artificial intelligence (AI) in pediatric cancer research, aiming to improve identification and treatment outcomes for childhood cancers. This policy underscores the growing role of AI in enhancing healthcare sectors, backed by rapid AI market growth, projected to increase from $25 trillion to $29 trillion by year-end, highlighting the technology’s accelerating impact (Source ID 87189).
Parallel to governmental efforts, pharmacists are embracing AI technologies to transform healthcare delivery. Don Roosan, PharmD, PhD, from Merrimack College, explains that pharmacy practice is evolving through telepharmacy and AI integration, enabling pharmacists to conduct thorough medical reviews, monitor chronic diseases, and educate patients virtually. AI is framed as an instrumental tool that augments pharmacy operations, such as predicting inventory needs, which allows pharmacists to focus more on patient care rather than replacing human expertise. However, challenges including data privacy and algorithmic bias are concerns that necessitate ethical oversight and human involvement (Source ID 87190).
Together, these developments reveal a broad healthcare trend wherein AI not only powers cutting-edge research—like pediatric oncology advancements—but also enhances frontline healthcare services such as pharmacy operations. The executive order signed by President Trump specifically advances childhood cancer research through AI, marking a significant policy initiative to harness this technology’s potential for life-saving medical progress.
Concurrently, pharmacy professionals are successfully navigating the intersection of digital innovation and clinical roles, highlighted by the expansion of telepharmacy services and the balanced integration of AI tools. These shifts reflect a healthcare ecosystem increasingly reliant on AI capabilities, while maintaining the indispensable role of human judgment and ethical vigilance.
These combined advancements signal a new era of AI-assisted healthcare, with promising impacts on patient outcomes and operational efficiency poised to grow in the near future.